Table 5.
Comparisons between patients with and without BKV replication within bone marrow.
| Patients with BKV replication in bone marrow: n = 8 | Patients without BKV replication in bone marrow: n = 64 | P value | |
|---|---|---|---|
| Male gender (%) | 6 (75%) | 34 (53%) | ns |
| Age (years) | 61 ± 8 | 56 ± 12 | ns |
| Serum creatinine (µmol/L) | 326 ± 250 | 197.3 ± 107 | 0.05 |
| DFG (mL/min) | 22.4 ± 15 | 36.3 ± 21 | 0.04 |
| Retransplantation (%) | 1 (12.5%) | 12 (19%) | ns |
|
| |||
| Immunosuppressive therapy | |||
| RATG (%) | 5 (62.5%) | 24 (37.5%) | ns |
| Rituximab (%) | 2 (25%) | 11 (17%) | ns |
| Steroid pulses (%) | 4 (50%) | 20 (31%) | ns |
| Plasma exchange (%) | 2 (25%) | 13 (20%) | ns |
| CNIs at bone-marrow analysis (%) | 6 (75%) | 57 (89%) | ns |
| MPA at bone-marrow analysis (%) | 7 (87.5%) | 53 (83%) | ns |
| MPA dose at bone-marrow analysis (mg/kg/d) | 12 ± 4 | 18 ± 8 | ns |
| Steroid-sensitive acute-rejection episodes (%) | 3 (5%) | 10 (15.6%) | ns |
| Steroid-resistant acute-rejection episodes (%) | 1 (12.5%) | 8 (12.5%) | ns |
| Antibody-mediated rejection episodes (%) | 2 (25%) | 8 (12.5%) | ns |
| Hemoglobin level at bone-marrow analysis (g/dL) | 12.4 ± 2.13 | 10.85 ± 1.77 | 0.06 |
| PMN counts at bone-marrow analysis (/mm³) | 695 (50–990) | 944 (20–8821) | ns |
| Platelet counts at bone-marrow analysis (/mm³) | 147,375 ± 67,692 | 156,593 ± 102,028 | ns |
| Lymphocyte counts (/mm³) | 600 (155–730) | 464 (27–3656) | ns |
| CD4-positive cell counts (/mm³) | 294 (34–884) | 183 (31–2012) | ns |
| CD8-positive cell counts (/mm³) | 223 (27–790) | 161 (12–1293) | ns |
| CD19-positive cell counts (/mm³) | 51 (0–918) | 35 (0–239) | ns |
| Gamma globulin levels (g/L) | 5.7 (4.5–7.8) | 6.9 (2.7–14) | ns |
| BK viremia at bone-marrow analysis (%) | 5 (62.5%) | 4 (6.25%) | 0.0004 |
| Cytomegalovirus viremia (%) | 0 (0%) | 9 (14%) | ns |
RATG: rabbit anti-thymocyte globulins; CNIs: calcineurin inhibitors; MPA: mycophenolic acid; PMN: polymorphonuclear leukocytes.